Advances in understanding drug metabolism and its contribution to variability in patient response

Therapeutic Drug Monitoring

Volumn 22, Issue 1, 2000, Pages 110-113

  Tucker, Geoffrey T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

CYP2D6; Cytochromes P450; Pharmacogenetics

Indexed keywords

CAFFEINE; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 2D6; DEBRISOQUINE; DEXTROMETHORPHAN; DRUG METABOLITE; MEPHENYTOIN; MIDAZOLAM; TOLBUTAMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; ECONOMIC ASPECT; ENZYME ACTIVITY; GENETIC VARIABILITY; GENOTYPE; PHARMACOGENETICS; PRIORITY JOURNAL;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG MONITORING; ENZYMES; HUMANS; MOLECULAR BIOLOGY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 0033953522     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200002000-00023     Document Type: Article

References (28)

1. Tucker GT. The in vitro assessment of human hepatic drug metabolism. In: O'Grady J and Joubert P, eds. Handbook of Phase I/II Clinical Drug Trials. Boca Raton: CRC Press; 1997:51-63.
2. Clarke SE. In vitro assessment of human cytochrome P450q. Xenobiotica 1998;28:1167-02.
3. Eddershaw PJ, Dickens M. Advances in in vitro drug metabolism screening. Pharmaceut Sci Technol Today 1999;2:13-9.
4. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequency and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
5. Marez D, Legrand M, Sabbagh N, Lo Giudice J-M, Spire C, Lafitte J-J, Meyer UA, et al. Polymorphism of the cytochrome P450 2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193-202.
6. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, et al. Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998;8:15-26.
7. Aklillu E, Persson I, Bertilsson L, Johansson i, Rodrigues F, Ingelman-Sundberg M. Frequency distribution of ultrarapid metabolizers of debrisoquine in an Ethiopean population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996:278:441-6.
8. Frye RF, Matzke GR, Adeyoin A, Porter JA, Branch RA. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997;62:365-78.
9. Tucker GT, Rostami-Hodjegan A, Jackson PR. Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. Xenobiolica 1998;28:1255-73.
10. Rostami-Hodjegan A, Kroemer HK, Tucker GT. In vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics 1999;9:277-86.
11. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 1994;46 (suppl.1):417-24.
12. Tucker GT. Clinical aspects of polymorphic drug metabolism. In: Erill S, Tucker GT, eds. Variation in human drug response. Amsterdam: Elsevier (in press).
13. Levy G, Ebling WF, Forrest A. Concentration-or effect-controlled clinical trials with sparse data. Clin Pharmacol Ther 1994;56:1-8.
14. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997;51:395-8.
15. Chen S, Chou W-H, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry, Clin Pharmacol Ther 1996;60:522-34.
16. Spina E, Marlines C, Caputi AP, Cobaleda J, Pinas B. Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 1991;41:467-70:
17. Llerena A, Kiivet R. Fixed combination of neuroleptics with antidepressants: potential risks and estimation of use. Br J Clin Pharmacol 1994;37:531-2.
18. Rosholm J-U, Hallas J, Gram LF. Concurrent use of more than one major psychiatric drug (polypsychopharmacy) in out-patients - a prescription database study. Br J Clin Pharmacol 1994;37:533-8.
19. Jerling M. Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration response. Eur J Drug Metab Pharmacokin 1996:21:113-21.
20. Linnet K, Wiborg O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther 1996;60:41-7.
21. Westermeyer J. Fluoxetine-induced tricyclic toxicity: extent and duration. J Clin Pharmacol 1991:31:388-92.
22. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
23. Brosen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991;32;136-7.
24. Sindrup SH, Brosen K, Gram L, Hallas J, Skjelbo E, Allen A, Allen GD, et al. The relationship between paroxetine and sparteine oxidation polymorphism, clin Pharmacol Ther 1992:51:278-87.
25. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
26. Haining RI, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate steroselectivity and prochiral selectivity of the wild-type ans 1359L mutant forms. Arch Biochem Biophys 1996;333:447-58.
27. Aithal GP, Day CP, Ketseven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353: 717-9.
28. Wedlund PJ, de Leon J, Davis G. Pharmacogenetic testing in the clinic and cost comparisons. In: Proceedings of the VII Stowe Symposium, UK Drug Metabolism Group; July 1999; Stoke Rochford, UK